# Yinapu (Zhejiang) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yinapu-zhejiang-biotechnology-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.imsynp.com
- Latest round: Series A (Mar 25, 2022)
- Investors on record: 3

## About

Based in Hangzhou, China and founded 2016, Yinapu (Zhejiang) Biotechnology Co., Ltd. operates as a developer of intelligent diagnostic products, providing patients with medical testing services such as metabolic testing, nucleic acid testing, and health testing. The company was awarded as Special Gold Award of the Second China University Science and Technology Achievement Fair.

The services of the company can be categorized into four categories which are metabolic testing, nucleic acid testing, health testing, scientific research cooperation. Services within include ancillary diagnosis of small pulmonary nodules, endocrine metabolism testing, etc. The company established a molecular group engineering platform for major diseases and intelligent mass spectrometry medical detection and analysis platform iMS-Clinics system which can complete high-throughput rapid screening and identification of metabolic markers in trace body fluid samples. The company also has cooperation with Shanghai Jiao Tong University, Fudan University, Stanford University, Shanghai Chest Hospital, Renji Hospital, etc.

The company will focus on the development and certification of in vitro diagnostic product pipeline, iteration and expansion of metabolome engineering platform, as well as the construction and deepening of marketing and service network. Based on the existing platform, the company will further accelerate the reporting of in vitro diagnostic kits.

## Funding rounds

- Series A, Mar 25, 2022 — Watson Capital, Reigncom, Jiaxing Shicui Medical Industry Investment

## Investors

- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series A
- Reigncom — Series A
- Jiaxing Shicui Medical Industry Investment — Series A